Nombre del producto:(S)-2-((4-(Trifluoromethyl)phenoxy)methyl)oxirane

IUPAC Name:(2S)-2-{[4-(trifluoromethyl)phenoxy]methyl}oxirane

CAS:256372-58-4
Fórmula molecular:C10H9F3O2
Pureza:95%+
Número de catálogo:CM538737
Peso molecular:218.18

Unidad de embalaje Stock disponible Precio($) Cantidad
CM538737-1g 1-2 Weeks ƚƴǫƐ
CM538737-5g 1-2 Weeks ȅƚƚŪ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :256372-58-4
Fórmula molecular:C10H9F3O2
Punto de fusión:-
Código de sonrisas:FC(C1=CC=C(OC[C@H]2OC2)C=C1)(F)F
Densidad:
Número de catálogo:CM538737
Peso molecular:218.18
Punto de ebullición:
Nº Mdl:MFCD09027623
Almacenamiento:

Category Infos

Oxiranes
Oxirane is a three-membered ring compound consisting of one oxygen atom and two carbon atoms. Oxirane is present in natural products such as cryptocin, which has anticancer properties, and azidomycin, trienone, and epoxidomycin, which have shown activity against drug-resistant leukemias and AIDS-related lymphomas. Other oxirane containing bioactive molecules have anti-inflammatory, immunosuppressive, and antitumor activities. Oxiranes are a strained ring susceptible to various nucleophilic, ring-opening or rearrangement reactions, so they are considered to be one of the most important intermediates in organic synthesis.

Column Infos

Seladelpar
Recently, CymaBay Therapeutics announced it has submitted a New Drug Application (NDA) to the FDA for investigational treatment, seladelpar, for the management of primary biliary cholangitis, including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid (UDCA). CymaBay has requested a Priority Review of the NDA that, if accepted, would mean the FDA would plan to complete its review within six months of accepting the application. Seladelpar has been granted Breakthrough Therapy Designation by the FDA and is the only potent, selective, orally active delpar, or PPARδ agonist, with Phase 3 trial results demonstrating a statistically significant improvement in markers of cholestasis related to risk of progression and PBC-related pruritus.

Related Products